Alexion: Trading around Volume Profile POCIf you like this idea, don't forget to hit the Like Button!
Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish.
However, from a technical point of view, we are in a critical consolidation phase that started at the end of October 2019. The stock price is consolidating around $107.88 level.
What to do now?
I would wait for Alexion to exit the consolidation phase with a breakout. My signal is the break of the $116.61 important resistance. Look at the purple line in the graph (Developing POC) to monitor interesting volumes movements able to push up the price (in the chart Developing POC is overlapping the POC red line). I suggest to not go in with a trade immediately after the resistance breakout since Alexion presents high uncertainty. Thus wait for a confirmation green candle (daily).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Biopharma
Imminent break to the upside for Clovis Oncology.I think we will see a sharp move this month. From reading the chart alone I am wagering it's going to be a bullish move... even though the fundamentals of the company are up for debate.
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud).
I was waiting for today's opening to confirm a bullish position.
Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
ICO Therapeutics breakout over .07 Alpha Scalper turned to longAbnormal volume breakout with next resistance at .095
BIOS Bullish Cup and HandleBIOS looks to potentially be in a bullish cup and handle pattern that could potential send the stock to $6.
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move?
"Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61."
Original Article: 4 Penny Stocks To Watch Under $4
NASDAQ:NTEC
Sangamo's: Doom or Gloom ScenarioRecent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up.
Some traders do not believe in technical analysis, that's fine, but I think you may want to re-consider and hear me out on this one. Most didn't believe in Sangamo either (aren't I right Sangamo fan's)!!
What Does The Chart Say?
The long-term pattern (from day of IPO) suggests that if Sangamo Therapeutics stock price continued its trend, it was a possibility that pattern would repeat therefore potentially pulling back to December 2016 lows of around $3.67. Although this may still be a possibility, Sangamo caught wind in its sails on good data release recently, re-igniting investor optimism. I remain cautiously optimistic with Sangamo, so I went ahead and put together a short-term game plan just in case. Take a look at short list of what I will be watching for while I wait for further confirmation of long-term trend indication.
When making previous highs, Sangamo's stock price has entailed devastating 5-wave corrections, however:
The daily chart suggests that instead of a 5-wave correction that could potentially take SGMO to sub $4, SGMO's chart details an AB=BC corrective wave that could potentially mark the low of the long-term selloff.
AB=BC corrective waves are equal in length/or magnitude and on a Bullish correction would bounce off the 0.786 retracement level.
SGMO had a sharp bounce off this level in Feb 2019 and closed the day right above the 0.786 retracement zone. This is a very important level of support to close upon.
If this did not happen I would be on the other side of the trade waiting for a wash, down to $4. But from my experience there still may be fighting chance.
Short-term (from Feb 2019 to now) SGMO continues to make higher lows, this is #Bullish.
Although SGMO looks to have failed to break current resistance in the chart above,volume/optimism packed enough punch to test $11.85 which is a 1.618 Fibonacci extension (normal extensions range from 1.272 or 1.414).. . #Bullish
May not be exactly what a Long-term investor's of SGMO would want to hear, but a pullback around .618-.786 retracement (shown in green-zone on chart) would be a nice place to add for swing-trade up to earnings.
Previous earnings have brought 10-20% run-ups, but be careful to not get trapped in an earnings selloff.
If SGMO continues to make higher-lows, this could be a potential range to be looking for a swing position.
Breakout of this zone could mean big $$
Fall below blue trend line could mean devastation
my stop-loss will be set below blue trend-line.
Again, it's a long way down to $4 if trend continues to follow its Long-term pattern. Previous trends have issued 5-wave correction, peak to trough, the current pattern details an AB=BC harmonic pattern (outlined in #RED) please press play and zoom out to see what I am referring to.
Tip # 5 : A trend line in mathmatical terms means the line of best fit. When using them, make sure they touch as many points as possible on the chart.
Please like and follow so I can continue doing technical analysis. Thank you in advance everyone =)
@VolatilityWatch
@scooby_snack
Disclosure: I do not own SGMO. I may buy/sell within the next 72 hours. This is not a note to buy or sell. Please do your homework before investing.
//----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Check out my some of my current trades.
TRVN: Trend PlayThis stock popped up on my stock screener the other day.
I wanted to document this trade in case it ends up going well.
What I'm seeing here on the daily is a break above it's 100 then 200 MA. Now we are in this consolidation period with a little coiling action happening within the triangle I've drawn.
It's clear price is going to break in an explosive way whether that's up or down.
I have a stop limit placed at $1.68 for a break out to the upside.
I will move my stop loss up as price advances to lock in gains.
Check out Assetguild.com for more detailed analysis and blog content.
ADAMIS PHARMACEUTICALS CORPORATION PDUFA Date 9/27Here is a good resource for more stocks like this www.biopharmcatalyst.com
The only stocks I trade currently are biopharma stocks with FDA approvals coming. I know the date there will be price action just need a good entry.
Celgene ($celg) if tomorrow...if only tomorrow....Weekly chart: we have the downtrend channel clearly defined on a weekly basis. On a monthly basis we have already had a minimum of swing with a dragon fly bullish, on a daily chart some signs of an incoming uptrend as described in the latest posts...but tomorrow...tomorrow is where we play the game with the last resistence in place at 86.72 dollars. Once we get out of the channel and we leave this solid resistance it will mean that Celgene will be ready to come back to war.
I will be long in case the price breaks such thresold because signs of long will get really clear.
$RDGL Vivos INC; clean break, big potentialI need to do more research before offering a formal opinion, but i bought for TA reasons at 0035 so i wanted to share the chart now that it's making a real move and the cancer drug they make is showing promise. Looks like we could see .01 before a pullback, but the volume is insane so who knows where it ends up.
$NEOS NEOS Therapeutics; broke LT downtrend, could runAnother pharma stock here for those interested. These are often hit or miss, but NEOS has a solid floor and a lot of room to move if it gets going. Worth watching and maybe taking a shot with a small bet (not financial advice -- do we really have to say that when were obviously just finger-painting projections?) haha, GLTA!
KTOV FDA Approval take gains and get out As expected KTOV passed the FDA approval time to take some gains and move on to the next one.
finance.yahoo.com
A Low Beta Way to Play Biopharma IndustryAttached is a piece about SWKH in which I discuss the value within the company, and I suggest it as a way of exposure to the healthcare technology sector without the risk. How is that possible? SWKH uses debt investments when making acquisitions in companies. Debt investments are usually the first investments to be paid back in full when a company undergoes liquidation / bankruptcy. Give it a read and let me know what y'all think.
rockvuecapital.wordpress.com
All the best,
RC
Biotech's 40% Bear Market is OverThere is one useful way to determine when a trend is over and that is using a 50% "speedline" of a move.
The decline from $400 in $IBB, the IShares Nasdaq Biotechnology Index Fund back in July 2015 and then tumbled 40% to $240 on February 9th, 2016 and later retested $240 on June 27, 2016.
The mid-point of that decline is $320 and a line drawn from the top at $400 down through the $320 level on June 27th gives you a line that is now down below $275 and that line has been violated to the upside, retested and is turning back up again and THIS TIME it is with President Trump pushing for faster "time to market" in exchange for lower drug prices. Will the deal go through and will it make a difference? Time will tell.
For now, the Yellen-Bubble-popping bear market has been dramatic since August 2015 as it tumbled a whopping 40%.
But there might be signs of life here in Biotech Bubble land, even with fears of price gouging still lingering over these stocks .
For now: Average in over the next 2-3 months and see if this story pans out.
Tim
12:31AM EST February 2, 2017 280.42 last $IBB. Other symbols for Biotech $FBT, $XBI, $BBH